Use of tenecteplase, a variant of alteplase with an 80‐fold reduction in sensitivity to PAI‐1,42 was able to restore the fibrinolytic potential in plasma from patients with COVID‐19 with high PAI‐1 levels. The gene discussed is SERPINE1; the disease is COVID-19.